کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10964880 | 1102729 | 2014 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ASCTTDPRNFHAantibody secreting cells - آنتی بادی ترشح سلول هاtetanus toxoid - توکسوئین تانتانسB cells - سلول های Bpertussis toxin - سموم سورافنیPertussis - سیاه سرفهFilamentous hemagglutinin - هموگلوتینین رشته ایAcellular pertussis vaccine - واکسن کوسه ای ساکولاWhole cell pertussis vaccine - واکسن کوسه عصبی مرکبPertactin - پرتاکتینPhase I clinical trial - کارآزمایی بالینی فاز اول
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
ایمونولوژی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Despite high vaccination coverage, pertussis is still a global concern in infant morbidity and mortality, and improved pertussis vaccines are needed. A live attenuated Bordetella pertussis strain, named BPZE1, was designed as an intranasal vaccine candidate and has recently been tested in man in a phase I clinical trial. Here, we report the evaluation of the B-cell responses after vaccination with BPZE1. Forty-eight healthy males with no previous pertussis-vaccination were randomized into one of three dose-escalating groups or into a placebo group. Plasma blast- and memory B-cell responses were evaluated by ELISpot against three different pertussis antigens: pertussis toxin, filamentous haemagglutinin and pertactin. Seven out of the 36 subjects who had received the vaccine were colonized by BPZE1, and significant increases in the memory B-cell response were detected against all three tested antigens in the culture-positive subjects between days 0 and 28 post-vaccination. The culture-positive subjects also mounted a significant increase in the filamentous haemagglutinin-specific plasma blast response between days 7 and 14 post-vaccination. No response could be detected in the culture-negatives or in the placebo group post-vaccination. These data show that BPZE1 is immunogenic in humans and is therefore a promising candidate for a novel pertussis vaccine. This trial is registered at ClinicalTrials.gov (NCT01188512).
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Vaccine - Volume 32, Issue 27, 5 June 2014, Pages 3350-3356
Journal: Vaccine - Volume 32, Issue 27, 5 June 2014, Pages 3350-3356
نویسندگان
Maja Jahnmatz, Sylvie Amu, Margaretha Ljungman, Lena Wehlin, Francesca Chiodi, Nathalie Mielcarek, Camille Locht, Rigmor Thorstensson,